The receipt of a A$2.6 million R&D tax incentive is significant for Immutep as it directly supports the company's research activities in France. This financial benefit is likely to have a positive impact on the company's short-term financial stability and could be viewed favorably by investors, potentially leading to an uptick in the stock price. The high relevance score is due to the direct mention of Immutep and the nature of the news. The importance is rated at 75, considering that R&D incentives can substantially support biotech companies' operations. The confidence level is at 90, reflecting the clear positive nature of the news but leaving room for market unpredictability.